Cleerly, Inc. Overview
Pro stress-test →Cleerly is a healthcare company on a mission to eliminate heart attacks by creating a new standard of care for coronary artery disease through FDA-cleared AI-driven solutions that support comprehensive phenotyping using advanced non-invasive CT imaging. The company delivers actionable clinical insights across the entire cardiac care pathway, addressing a critical gap in early disease detection and prevention.
Strategic Profile
Pro stress-test →Cleerly completed a Series C funding round in November 2024, and recently achieved Medicare coverage and a CPT Category I code for advanced plaque analysis, positioning itself as a market leader in AI-enabled cardiovascular diagnostics. As of May 31, 2026, the company has 354 employees, demonstrating significant scaling momentum in a competitive but undersaturated market.
Competitive Landscape
Pro stress-test →Top competitors include HeartFlow, Lantheus, and VentriPoint. Cleerly differentiates through comprehensive plaque phenotyping from non-invasive CT, FDA clearance, and integrated clinical-AI approach grounded in large multi-patient datasets. The competitive landscape is consolidating around AI-enabled diagnostics with significant regulatory and reimbursement barriers to entry.
Industry Context
Cleerly, Inc. operates in AI-driven cardiovascular diagnostics.
Key facts
Founded: 2016 · Headquarters: New York, US · Employees: 354 · Revenue: N/A · Market cap: N/A